SIGILON THERAPEUTICS INC (SGTX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SGTX • US82657L2060

22.47 USD
-0.59 (-2.56%)
At close: Aug 10, 2023
23 USD
+0.53 (+2.36%)
After Hours: 8/10/2023, 8:02:09 PM
Fundamental Rating

1

Overall SGTX gets a fundamental rating of 1 out of 10. We evaluated SGTX against 524 industry peers in the Biotechnology industry. SGTX has a bad profitability rating. Also its financial health evaluation is rather negative. SGTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • SGTX had negative earnings in the past year.
  • SGTX had a negative operating cash flow in the past year.
SGTX Yearly Net Income VS EBIT VS OCF VS FCFSGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 0 20M -20M -40M -60M -80M

1.2 Ratios

  • SGTX has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SGTX Yearly ROA, ROE, ROICSGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -500 -1K -1.5K -2K -2.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SGTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGTX Yearly Profit, Operating, Gross MarginsSGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 -200 -400 -600 -800

More info and screens

2

2. Health

2.1 Basic Checks

  • SGTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SGTX has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, SGTX has a worse debt to assets ratio.
SGTX Yearly Shares OutstandingSGTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 10M 20M 30M
SGTX Yearly Total Debt VS Total AssetsSGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -4.91, we must say that SGTX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of SGTX (-4.91) is worse than 68.20% of its industry peers.
  • A Debt/Equity ratio of 0.31 indicates that SGTX is not too dependend on debt financing.
  • The Debt to Equity ratio of SGTX (0.31) is worse than 73.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -4.91
ROIC/WACCN/A
WACC9.94%
SGTX Yearly LT Debt VS Equity VS FCFSGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

  • SGTX has a Current Ratio of 2.23. This indicates that SGTX is financially healthy and has no problem in meeting its short term obligations.
  • SGTX's Current ratio of 2.23 is on the low side compared to the rest of the industry. SGTX is outperformed by 80.27% of its industry peers.
  • A Quick Ratio of 2.23 indicates that SGTX has no problem at all paying its short term obligations.
  • SGTX's Quick ratio of 2.23 is on the low side compared to the rest of the industry. SGTX is outperformed by 78.57% of its industry peers.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 2.23
SGTX Yearly Current Assets VS Current LiabilitesSGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

  • SGTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -327.88%.
  • SGTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 49.27%.
  • Measured over the past years, SGTX shows a decrease in Revenue. The Revenue has been decreasing by -2.95% on average per year.
EPS 1Y (TTM)-327.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-595.35%
Revenue 1Y (TTM)49.27%
Revenue growth 3Y-2.95%
Revenue growth 5YN/A
Sales Q2Q%53.49%

3.2 Future

  • SGTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.31% yearly.
  • Based on estimates for the next years, SGTX will show a decrease in Revenue. The Revenue will decrease by -0.28% on average per year.
EPS Next Y-34.47%
EPS Next 2Y-35.84%
EPS Next 3Y-16.93%
EPS Next 5Y13.31%
Revenue Next Year19.62%
Revenue Next 2Y10.18%
Revenue Next 3Y6.68%
Revenue Next 5Y-0.28%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SGTX Yearly Revenue VS EstimatesSGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 5M 10M 15M
SGTX Yearly EPS VS EstimatesSGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SGTX. In the last year negative earnings were reported.
  • Also next year SGTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGTX Price Earnings VS Forward Price EarningsSGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGTX Per share dataSGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

  • SGTX's earnings are expected to decrease with -16.93% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.84%
EPS Next 3Y-16.93%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for SGTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SIGILON THERAPEUTICS INC / SGTX FAQ

What is the fundamental rating for SGTX stock?

ChartMill assigns a fundamental rating of 1 / 10 to SGTX.


What is the valuation status for SGTX stock?

ChartMill assigns a valuation rating of 0 / 10 to SIGILON THERAPEUTICS INC (SGTX). This can be considered as Overvalued.


Can you provide the profitability details for SIGILON THERAPEUTICS INC?

SIGILON THERAPEUTICS INC (SGTX) has a profitability rating of 0 / 10.


What is the earnings growth outlook for SIGILON THERAPEUTICS INC?

The Earnings per Share (EPS) of SIGILON THERAPEUTICS INC (SGTX) is expected to decline by -34.47% in the next year.